AB Corporate Bond ETF (NASDAQ:EYEG) Shares Cross Below Fifty Day Moving Average – Should You Sell?

Posted by Logan Wallace on Sep 9th, 2026

AB Corporate Bond ETF (NASDAQ:EYEG – Get Free Report) shares crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $34.68 and traded as low as $34.38. AB Corporate Bond ETF shares last traded at $34.39, with a volume of 23 shares changing hands.

AB Corporate Bond ETF Price Performance

The company has a market capitalization of $27.51 million, a P/E ratio of -20.47 and a beta of 0.18. The business’s 50-day simple moving average is $34.68 and its 200 day simple moving average is $35.11. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01.

AB Corporate Bond ETF Cuts Dividend

The business also recently disclosed a monthly dividend, which was paid on Friday, September 4th. Investors of record on Tuesday, September 1st were paid a dividend of $0.1284 per share. This represents a c) dividend on an annualized basis and a dividend yield of 4.5%. The ex-dividend date was Tuesday, September 1st. AB Corporate Bond ETF’s dividend payout ratio (DPR) is currently -101.79%.

Institutional Investors Weigh In On AB Corporate Bond ETF

An institutional investor recently bought a new stake in AB Corporate Bond ETF stock. Kestra Advisory Services LLC bought a new position in AB Corporate Bond ETF (NASDAQ:EYEG – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 951 shares of the specialty pharmaceutical company’s stock, valued at approximately $34,000. Kestra Advisory Services LLC owned 0.13% of AB Corporate Bond ETF at the end of the most recent reporting period. 64.16% of the stock is owned by hedge funds and other institutional investors.

AB Corporate Bond ETF Company Profile

(Get Free Report)

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.